350 Принципы и практика психофармакотерапии

10. Petit JM, Spiker DG, Ruwitch JF, et al. Tricyclic antidepressant plasma levels and adverse effects after overdose. Clin Pharmacol Ther 1977; 21: 47-51.

11. Preskorn SH, Irwin H. Toxicity of tricyclic anti-depressants: kinetics, mechanisms, intervention: a review. Clin Psychiatry 1982; 143:151-156.

12. Vohra J, Burrows G, Hunt D, et al. The effects of toxic and therapeutic doses of tricyclic antide­pressant drugs on intracardiac conduction. Eur J Cardiol 1975; 3:219-227.

13. Rudorfer MB, Young RG. Desipramine: cardiovas­cular effects and plasma levels. Am J Psychiatry 1980; 137:984-986.

14. Veith RC, Friedel RO, Bloom B, et al. Electrocar­diogram changes and plasma desipramine levels during treatment. Clin Pharmacol Ther 1980:27: 796-802.

15. Preskorn SH, Weller E, Weller R, et al. Plasma lev­els of imipramine and adverse effects in childrea Am J Psychiatry 1983; 140:1332-1335.

16. Katz IR, Simpson GMJetanandoni V, et al. Steady-state pharmacokinetics of nortriptyline in the frail elderly. Neuropsychopharmacology 1989; 2 (3): 229-236.

17. Bjerkenstedt L, Flyckt L, Overo KF, Lingjaerde 0. Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram. Eur J Clin Pharmacol 1985; 28: 553-557.

18. Dufour H, Bouchacourt M, Thermoz P, et al. Cita­lopram — a highly selective 5-HT reuptake inhibi­tor — in the treatment of depressed patients. Int Clin Psychopharmacol 1987; 2: 225-237.

19. Kelly M, Perry P, Holstad S, Garvey M. Serum fiuo-xetine and norfluoxetine concentrations and antidepressant response. Ther Drug Monit 1989; 11:165-170.

20. Preskorn SH, Silkey B, Beber J, Dorey C. Antidep­ressant response and plasma concentratipris of fluo-xetine. Ann Clin Psychiatry 1991; 3 (2): 147-151.

21. Kasper S, Dotsch M, Vieira A, Kick H, Moller HJ. Plasma concentration of fluvoxamine and mapro-tiline in major depression: implications on ther­apeutic efficacy and side effects. Eur Neuropsy-chopharmacol 1992; 3:13-21.

22. Laursen AL, Mikkelsen PL, Rasmussen S, ie Fevre HP. Paroxetine in the treatment of depression— a randomized comparison with amitriptyline. Acta Psychiatr Scand 1985; 71: 249-255.

23. Tasker TCG, Kaye CM, Zussman BD, Link CG. Par­oxetine plasma levels: lack of correlation with

efficacy or adverse events. Acta Psychiatr Scand 1989; 80:152-155.

24. Preskorn S, Harvey A. Biochemical and clinical dose-response curves with sertraline. Clin Phar­macol Ther 1996; 59 (2): 180.

25. Preskorn SH. Clinical pharmacology of selective serotonin reuptake inhibitors, 1st ed. Caddo, OK Professional Communications, 1996.

26. Nefazodone presentation to the Food and Drug Administration Psychopharmacology Advisory (PDA) Committee. Washington, DC, July, 1993-

27. Kaul S, Shukia UA, Barbhaiya R. Nonlinear phar­macokinetics of nefazodone after escalating single and multiple oral doses. J Clin Pharmacol 1995; 35:830-839.

28. Mayol R, Cole C, Luke G, et al. Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma. Drug Metab Dispos 1994; 22: 304-311.

29. Franc J, Duncan G, Farmen R, et al. High-perfo-mance liquid chromatographic method for the determination of nefazodone and its metabolites in human plasma using laboratory robotics. J Chromatogr Biomed Appl 1991; 570:129-138.

30. Maitre L, Baumann PA, Jaekel J, Waldmeier PC. 5-HT uptake inhibitors: psy-chopharmacological and neurobiochemical criteria of selectivity. In: Ho ВТ, Schoolar J, Usdin E, eds. Serotonin in biological psychiatry. New York Raven Press, 1982; 229-246.

31. Caccia S, Ballabio M, Samanin R, et al. (-)-m-Chlo-rophenyl-piperazine, a central 5-hydroxytryptar-nine agonist, is a metabolite of trazodone. J Pharm Pharmacol 1981; 33:477-478.

32. Preskorn SH. Antidepressant response and plas­ma concentrations of bupropion. J Clin Psychia­try 1983; 44(5): 137-139.

33. Golden RN, DeVane CL, Laizure SC, et al. Bupropi­on in depression, II: The roles of metabolites in cli­nical outcome. Arch Gen Psychiatry 1988; 45:145-149.

34. Davidson J. Seizures and bupropion: a review. J Clin Psychiatry 1989; 50: 256-261.

35. Preskorn SH, Fleck RJ, Schroeder DH. Therapeu­tic drug monitoring of bupropion. Am J Psychia­try 1990; 147:12,1690-1691.

36. Ravaris CL, Nies A, Robinson DS, et al. A multi­ple-dose, controlled study of phenelzine in de­pression-anxiety states. Arch Gen Psychiatry 1976; 33: 347-350.

37. Bresnahan DB, Pandey GN, Janicak PG, Sharma R, Boshes RA. MAO inhibition and clinical res­ponse in depressed patients treated with phe­nelzine. J Clin Psychiatry 1990; 51:47-50.